AgingResearch.NewsJoin free
Alzheimer's & Dementia

Diabetes linked to lower Alzheimer's-related protein levels

Across three observational cohorts totaling 2,784 people, links with lower protein levels appeared mainly among participants with memory and thinking problems.

Paper by Min Wu, Ying Luan, Xiaowen Xu, +13 more authorsBenyan Luo · First Affiliated Hospital
Figure 1. Open in figure viewer Association of diabetes mellitus with amyloid and tau burden.
Open the figure at full size
Figure 1. Open in figure viewer Association of diabetes mellitus with amyloid and tau burden.Open in figure viewer Association of diabetes mellitus with amyloid and tau burden.Wu et al., CC BY

Our read

Populations
Studied:
Cohort study of 2,784 participants with and without diabetes, against participants without diabetes (Independent replication, multicenter)
What changed:
Brain amyloid beta levels were lower with diabetes in CPAS and ADNI, but did not differ in HABS-HD
The catch:
Cognitive impairment duration could confound the link with lower amyloid and tau levels
In the record:
The 740th paper on metformin with results in people; 2,329 on record in all.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

The 2,784 men and women in three observational cohorts included people with and without diabetes or cognitive impairment—memory or thinking difficulties. Average ages were 68.1, 73.7 and 65.7 years across the cohorts. Brain scans measured amyloid beta and tau, proteins that accumulate in Alzheimer's disease.

Diabetes was linked to lower levels of both proteins in the Chinese Preclinical Alzheimer's Disease Study and the Alzheimer's Disease Neuroimaging Initiative, particularly among participants with cognitive impairment. The community-based Health and Aging Brain Study–Health Disparities showed no clear differences. Among 625 Alzheimer's Disease Neuroimaging Initiative participants followed for an average of 3.5 years, those with diabetes showed slower decline in thinking and memory associated with a given starting level of tau.

Why it matters

Diabetes is a major risk factor for dementia. The authors suggest that diabetes-related biology and its management may influence the progression of Alzheimer's-related brain changes.

Caveats

Differences in diabetes medication use or blood vessel disease could have contributed to these links. The findings did not consistently extend to participants without cognitive impairment.

Where the evidence stands

Metformin

Cells, worms or flies, mice and humans: replicated by independent labs.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 569 independent labs in 69 countries
  • 262 findings against
  • 1,400 trials, 569 with no results posted
  • Funders: National Institutes of Health and others
  • 177 of 2,655 findings with company ties
  • 38 of 1,400 trials sponsored by its developers

MAPT

Worms or flies, mice and humans: replicated by independent labs. Cells: a single group.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

Includes the processes named after it and trials of drugs aimed at it.

  • 83 independent labs in 26 countries
  • 7 findings against
  • 11 trials
  • Funders: National Institute on Aging and others
  • 23 of 205 findings with company ties
  • 10 of 11 trials sponsored by developers of drugs aimed at it

From the paper

Participants

This study included 2784 participants from the CPAS (n = 734), ADNI (n = 835), and the HABS-HD (n = 1215), all of whom underwent both Aβ PET and tau PET imaging (Table 1).

Results, 3.1 Demographics

Follow-up

Longitudinal cognitive assessments were available for a subset of 625 participants in the ADNI cohort over a mean (SD) follow-up duration of 3.5 (1.7) years.

Results, 3.1 Demographics

Result

… diabetes was associated with lower Aβ Centiloids in CPAS (standardized β = −0.10; 95% confidence interval [95% CI], –0.17 to –0.04; p = 0.002, FDR corrected) and ADNI (β = −0.08; 95% CI, −0.14 to −0.03; p = 0.013, FDR corrected).

Results, 3.2 Lower Aβ and tau accumulation in DM

Quoted word for word from the full text on alz-journals.onlinelibrary.wiley.com.

Comments

Be the first to comment.

Metformin is part of Bryan Johnson's Blueprint and David Sinclair's daily regimen in Lifespan

The paper

Diabetes mellitus is associated with altered Alzheimer's disease pathology

Min Wu, Ying Luan, Xiaowen Xu, +13 more authorsBenyan Luo

First Affiliated Hospital

Alzheimer's & Dementia, Nov 10, 2026, Open access, CC BY

doi.org/10.1002/alz.72002

More on MAPT